Naurex reveals promising data with oral depression candidate
This article was originally published in Scrip
Executive Summary
Naurex has presented positive Phase II data with the second depression candidate in its pipeline, NRX-1074, an oral NMDA receptor partial agonist. This follows Phase IIb data reported recently with Naurex's lead program, GLYX-13, which also targets the NMDA receptor (scripintelligence.com, 11 December 2014).